Anna Goodman, Honorary Clinical Professor, Infectious Diseases
Anna has worked at the Unit in an honorary capacity since 2018, having previously been an NIHR Academic Clinical Lecturer at University College London and an MRC Clinical Research Fellow at the University of Oxford. She undertakes her clinical work at Guy’s and St Thomas’ NHS Foundation Trust where she is a consultant in Infectious Diseases and General Internal Medicine.
She has an interest in vaccines and undertook a DPhil at the University of Oxford where she worked on optimising technology for use in adenoviral vector vaccines for malaria. This technology was later incorporated into the novel SARS-CoV-2 vaccine AZD1222 (ChAdOx1). She has led the delivery of clinical trials of vaccines for malaria and COVID-19.
Current work focuses on the design and optimisation of pragmatic clinical trials in infectious diseases. She is undertaking research into bloodstream infections, such as S. aureus bacteraemia, and seeks to further explore the interplay with clinical imaging and clinical infection.
Selected publications
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, B Angus, VL Baillie, SL Barnabas, QE Bhorat, S Bibi, C Briner, P Cicconi, AM Collins, R Colin-Jones, CL Cutland , TC Darton, K Dheda, CJA Duncan, KRW Emary, KJ Ewer, L Fairlie, SN Faust, S Feng, DM Ferreira, A Finn, AL Goodman*, CM Green, CA Green…AD Douglas, AVS Hill, T Lambe, SC Gilbert, AJ Pollard; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99-111
Brown NM, Goodman AL*, Horner C, Jenkins A & Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC-Antimicrobial Resistance, 3, 1, 2021
Beigel JH et al., for the ACTT-1 Study Group Members*. Remdesivir for the Treatment of Covid-19 N Engl J Med 2020; 383:1813-1826.
SYC Tong, J Mora, AC Bowen, MP Cheng, N Daneman, AL Goodman*, GS Heriot, TC Lee, RJ Lewis, DC Lye, RK Mahar, J Marsh, A McGlothlin, Z McQuilten, SC Morpeth, DL Paterson , DJ Price, JA Roberts, JO Robinson, SJ van Hal, G Walls, SA Webb, L Whiteway, D Yahav, JS Davis; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe; Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476
Research Interests
- Infectious diseases vaccines
- Infectious diseases pragmatic clinical trials
- Clinical imaging in clinical infection
- Bloodstream infection
- aureus bacteraemia
Research Areas
- Infections
- S. aureus bacteraemia
- Vaccines
- Platform trials
UCL Profiles